Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
Retrieved on:
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Injection, Bristol Myers Squibb, Psoriasis Area and Severity Index, Aphthous stomatitis, Mouth, Allergy, Face, Friends, Week, Chronic pain, Infection, CPU socket, Clear, American Academy, Acne, Multimedia, Inflammation, National Psoriasis Foundation, Psoriasis, BMY, Yale School of Medicine, Hyperkinesia, Light, Dermatology, Eyelid, Patient, AAD, Sinusitis, Immune system, Conditional sentence, TYK2, PASI, NPF, Glycine mollis, FDA, Rash, Family, Tongue, NYSE, Skin, Disease, Pharmaceutical industry, Deucravacitinib, Chronicon
View the full release here: https://www.businesswire.com/news/home/20230804756518/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20230804756518/en/
Nitika, living with moderate to severe plaque psoriasis. - (Photo: Bristol Myers Squibb)
“I was young when I was diagnosed with moderate to severe plaque psoriasis, and it felt like my whole life revolved around my condition. - “This insight drove us to launch the Clear Understanding campaign to recognize those concessions and encourage people living with moderate to severe plaque psoriasis to talk to their dermatologist about available treatment options."
- In two studies of moderate to severe plaque psoriasis, Sotyktu was compared to placebo and Otezla® (apremilast).